Arsanis Out-Licenses Preclinical Stage Klebsiella pneumoniae Monoclonal Antibodies from ASN300 Program
- Category: More News
- Published on Thursday, 14 June 2018 18:32
- Hits: 500
Second recent transaction with Bravos Biosciences consolidates development of Arsanis gram-negative mAb candidates with global experts in anti-infective drug development
WALTHAM, MA, USA and VIENNA I Austria I June 14, 2018 I Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB200, LLC, a portfolio company of Bravos Biosciences, LLC, has secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license to selected monoclonal antibodies (mAbs) targeting K. pneumoniae that were discovered by Arsanis in its ASN300 program, including lead preclinical development candidate, ASN-5. In April 2018, Arsanis entered into a similar agreement for its ASN200 program, targeting E. coli, with Bravos Biosciences subsidiary BB100, LLC.
“Gram-negative bacteria are responsible for some of the most lethal and antibiotic-resistant hospital-acquired infections and we are excited that the expert team at Bravos Biosciences will continue to move these non-antibiotic monoclonal antibody programs forward,” said René Russo, chief executive officer of Arsanis. “With the successful out-licensing of antibodies from our ASN200 and ASN300 programs, we have completed our strategic goal of focusing our development pipeline while ensuring the potential advancement of these important gram-negative targeted mAbs under the leadership of a well-known expert team. This transaction allows Arsanis to focus on execution of our lead program, ASN100, currently in Phase 2 development for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients, and on ASN500 for respiratory syncytial virus infection, slated to begin clinical development in 2019.”
Under the agreement, Arsanis has granted BB200 the exclusive right to conduct further preclinical development activities on licensed mAbs, with an option to enter into an exclusive global development and commercial license. Arsanis retains the rights to all other mAbs developed in the ASN300 program.
About ASN300 and ASN-5
The ASN300 program is currently in preclinical development. As part of this program, Arsanis is developing monoclonal antibodies, including ASN-5, which have demonstrated rapid and targeted activity through various modes of action and provide high efficacy in relevant animal models of severe K. pneumoniae infections.
BB200 is a fully owned subsidiary of Bravos Biosciences, LLC. Paul G. Ambrose, Pharm.D., F.I.D.S.A., currently serves as president of the Institute for Clinical Pharmacodynamics (ICPD, Schenectady, NY). Both Bravos Biosciences and ICPD are cofounded by Drs. Ambrose, Sujata M. Bhavnani and Christopher M. Rubino. The team’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Dr. Ambrose has held academic appointments at the University of Oxford and the University at Buffalo as well as past industry positions including at Bristol Myers Squibb. Dr. Ambrose holds a Pharm.D. from the University of the Pacific and completed a Post-Doctoral Fellowship in infectious diseases at Hartford Hospital.
Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to what the company believes to be some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to further its goal of building and advancing a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus (RSV).
Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).